- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon reported a strong fiscal first-quarter with Operating Revenue up 15% YoY to Rs 3,942 Cr and EBITDA climbing 19% to Rs 829 Cr (both like-for-like). PBT before exceptional items jumped 72% to Rs 97 Cr. Biosimilars led segment growth at 18%. A successful Rs 4,500 Cr QIP bolstered the balance sheet, enabling increased Biocon Biologics ownership. Key product milestones include Yesafili™ launch in Canada and USFDA approval for interchangeable insulin biosimilar Kirsty™. New manufacturing facilities are also ramping up, positioning the company for continued growth.